

ASX Announcement

IMUGENE ANNOUNCES PUBLICATION OF CHECKVACC ABSTRACT AT ASCO 2022

SYDNEY, Australia, 31 May 2022: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to announce an abstract detailing its Phase 1 CHECKVacc trial in adults with triple negative breast cancer has been published at the American Society of Clinical Oncology's (ASCO) 2022 Annual Meeting.

The abstract is titled "Phase I study of intratumoral administration of CF33-HNIS-antiPDL1 in patients with metastatic triple negative breast cancer". The Principal Investigator leading the trial and lead author is Dr Yuan Yuan MD, PhD from City of Hope National Medical Center, Duarte CA.

The abstract can be viewed at <https://meetings.asco.org/abstracts-presentations/209942>

For more information please contact:

Leslie Chong

Managing Director and Chief Executive Officer
info@imugene.com

Investor Enquires

investor@imugene.com

Media Enquires

Matt Wright
matt@nwrcommunications.com.au

Follow us on Twitter @TeamImugene

Like us on Facebook @Imugene

Connect with us on LinkedIn @Imugene Limited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumors. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

*Release authorised by the Managing Director and Chief Executive Officer
Imugene Limited, Level 3, 62 Lygon Street, Carlton, VIC, 3053, Australia*